Centauri Therapeutics’ EUR 23.62 million funding round, led by the AMR Action Fund, puts fresh capital behind one of the more differentiated bets in the antimicrobial resistance (AMR) pipeline: using “programmable immunity” to redirect existing antibodies to kill pathogens.
The underwriting logic is straightforward. AMR remains a structurally under-incentivised therapeutic area, but the medical need is acute and worsening. Investors that are willing to finance platform risk are increasingly concentrating on assets that can credibly shorten time-to-effect, expand target coverage, or improve clinical differentiation versus conventional antibiotics. Centauri is positioning its Alphamer platform as a route to do exactly that.
Deal snapshot
- Target: Centauri Therapeutics (GB)
- Type: Funding
- Amount: EUR 23.62 million
- Investor: AMR Action Fund
- Sector: Healthcare (infectious disease and oncology platform)
- Timing: Recently announced
Disclosure on sourcing: available public reporting on Centauri’s recent fundraising references a GBP 8.1 million Series A (Feb 2026) and earlier GBP 3 million financing, and does not explicitly corroborate a EUR 23.62 million round led by the AMR Action Fund. Likewise, publicly cited backers include private investors, Discovery Park Technology Investment Fund, and Animatrix Capital, with no clear reference to AMR Action Fund. MidMarketNow has not independently verified the investor syndicate or round size beyond the deal facts provided.
Why this fits the current AMR funding playbook
This financing reads as a with-trend move: capital is flowing to AMR programmes that can be framed as platform-led and mechanistically distinct, rather than another incremental antibiotic.
Centauri’s Alphamer approach is based on chemically synthesised molecules designed to redirect naturally occurring antibodies to pathogens. In practice, Alphamers bind cell-surface targets on pathogens using aptamers and then recruit pre-existing antibodies, triggering an immediate antibacterial immune response.
For AMR, that mechanism matters. If the platform can repeatedly generate candidates against different pathogens and resistance profiles, it could support a portfolio model where multiple shots on goal are advanced in parallel rather than relying on a single antibiotic asset.
What Centauri is building
Centauri describes a pipeline spanning infectious disease and oncology, with assets in preclinical or discovery stages.
Verified disclosures indicate:
- Antibody drug conjugates (ADCs): 3 programmes
- Peptide drug conjugates (PDCs): 2 programmes
- Aptamer drug conjugates: 1 programme
Named examples include infectious disease candidates such as ABX-01 (Gram Negative Pneumonia) and ABX-05 (E. coli infections), alongside oncology work such as ACX-01 (Head and Neck Neoplasms).
The immediate strategic question is prioritisation. Infectious disease is the core AMR narrative, but oncology can offer clearer commercial comparables and potentially different partnering pathways. How Centauri sequences indications, and how it allocates this new capital between platform build-out and lead programme advancement, will drive time-to-value.
Key execution questions for the next 12-24 months
With terms undisclosed beyond headline amount, the main diligence focus shifts to execution and translation risk:
- Clinical translation of “programmable immunity.” Preclinical immune recruitment is compelling, but the clinical bar is proof of pathogen clearance, safety, and durability in heterogeneous patient populations.
- Manufacturing and CMC scalability. Chemically synthesised constructs can be an advantage, but the platform still needs reproducible manufacturing at clinical and commercial grade.
- Go-to-market and partnering strategy. AMR assets often require non-traditional commercialisation routes. The value inflection may come from partnerships, non-dilutive funding, or structured collaborations rather than a standalone launch.
- Portfolio discipline. A multi-modality pipeline can dilute focus. The company will need clear criteria for killing programmes and concentrating spend.
What to watch next
- Confirmation of round structure and syndicate (equity vs. tranched financing, participation, governance rights)
- Which lead programme is funded to a defined clinical milestone and the expected timing
- Any non-dilutive capital (grants, AMR initiatives) that extends runway
- Early signals on partnering appetite, particularly for infectious disease programmes
- Updates on CMC readiness and platform reproducibility across multiple pathogen targets